Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel therapeutic strategies for rare mutations in non-small cell lung cancer.

Scientific reports - 5 May 2024

Gou Qitao, Gou Qiheng, Gan Xiaochuan, Xie Yuxin

Abstract excerpt

Lung cancer is still the leading cause of cancer-related mortality. Over the past two decades, the management of non-small cell lung cancer (NSCLC) has undergone a significant revolution. Since the first identification of activating mutations in the epidermal growth factor receptor (EGFR) gene in 2004, several genetic aberrations, such as anaplastic lymphoma kinase rearrangements (ALK), neurotrophic tropomyosin...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Molecular Targeted Therapy

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-met

Source

Open in PubMed Open full text

Identifiers

PMID: 38705930
DOI: 10.1038/s41598-024-61087-2
PMCID: PMC11070427

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel therapeutic strategies for rare mutations in non-small cell lung cancer.PMID 38705930Read ↗

Targeted Therapy for Non-Small Cell Lung Cancer.Semantic proximity Read ↗

New horizons for uncommon mutations in non-small cell lung cancer: BRAF, KRAS, RET, MET, NTRK, HER2Semantic proximity Read ↗

Treatment of Patients With Non-Small-Cell Lung Cancer Harboring Rare Oncogenic Mutations.Semantic proximity Read ↗

KRAS and MET in non-small-cell lung cancer: two of the new kids on the 'drivers' block.Semantic proximity Read ↗

Emerging targeted therapies in non-small cell lung cancer.Semantic proximity Read ↗

Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Advances in the Treatment of Rare Epidermal Growth Factor Receptor Mutations in Advanced Nonsmall-Cell Lung Cancer.Semantic proximity Read ↗

New Targets in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Cutting edge therapies: A review of Food and Drug Administration-approved drugs for non-small cell lung cancer.Semantic proximity Read ↗

Overview on Therapeutic Options in Uncommon EGFR Mutant Non-Small Cell Lung Cancer (NSCLC): New Lights for an Unmet Medical NeedSemantic proximity Read ↗

Rare mutations in non-small-cell lung cancer.Semantic proximity Read ↗

Hitting the Right Spot: Advances in the Treatment of NSCLC With Uncommon EGFR Mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.